32 results on '"Vehling-Kaiser U"'
Search Results
2. 443TiP Impact of a centralized tumour board on secondary intervention rate in patients with RAS mutant metastatic colorectal cancer after first-line treatment with FOLFOXIRI plus bevacizumab (FIRE-7, AIO-KRK-0120)
3. 424P Avelumab added to FOLFIRI plus cetuximab followed by avelumab maintenance in patients with previously untreated RAS wild-type colorectal cancer: The phase-II FIRE-6 (AIO KRK-0118)
4. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer–subgroup analysis of patients with KRAS: mutated tumours in the randomised German AIO study KRK-0306
5. A prospective multicenter phase II study of oral and i.v. vinorelbine plus trastuzumab as first-line therapy in HER2-overexpressing metastatic breast cancer
6. PD-027 BRAF mutant and RAS mutant patients treated with FOLFIRI plus Bevacizumab or FOLFIRI plus Cetuximab. Role of ETS and molecular markers in FIRE-3 (AIO KRK-0306)
7. SO-6 Changes in the course of advanced pancreatic cancer treatment with systemic chemotherapy: A pooled analysis of five clinical trials from two decades of clinical research within the German AIO Study-Group
8. P-179 Prognostic and predictive value of CEA before initiation of therapy in the XELAVIRI trial
9. 441P Evaluation of conversion therapy in patients undergoing secondary resection of metastases in curative intent within the FIRE-3 (AIO KRK-0306) study
10. Age and RAS status to select patients with metastatic colorectal cancer (mCRC) for initial sequential versus combination therapy including fluoropyrimidines (FP), irinotecan (Iri) and bevacizumab (Bev): XELAVIRI- study
11. Sequential first-line therapy of metastatic colorectal cancer (mCRC) starting with fluoropyrimidine (FP) plus bevacizumab (BEV) vs. initial FP plus irinotecan (IRI) and BEV: German AIO KRK0110 (ML22011) study
12. PD-020 - Age and RAS status to select patients with metastatic colorectal cancer (mCRC) for initial sequential versus combination therapy including fluoropyrimidines (FP), irinotecan (Iri) and bevacizumab (Bev): XELAVIRI- study
13. 486O - Sequential first-line therapy of metastatic colorectal cancer (mCRC) starting with fluoropyrimidine (FP) plus bevacizumab (BEV) vs. initial FP plus irinotecan (IRI) and BEV: German AIO KRK0110 (ML22011) study
14. Independent Radiological Evaluation of Objective Response, Early Tumor Shrinkage, and Depth of Response in Fire-3 (Aio Krk-0306) in the Final Ras Evaluable Population
15. The Mobile Oncological Service for Out-Patients (Mod): Analysis of Cost Effectiveness and Quality of Life in the First Quarters of Action
16. Network Kids: a Project for Children of Cancer Patients. Analyses of Impact on Quality of Life and Coping for Families Affected
17. 2Nd-Line Therapies After 1St-Line Therapy with Folfiri in Combination with Cetuximab or Bevacizumab in Patients with Kras Wild-Type Metastatic Colorectal Cancer (Mcrc)-Analysis of the Aio Krk 0306 (Fire 3)- Trial
18. Independent Radiological Evaluation of Objective Response Early Tumor Shrinkage, and Depth of Response in FIRE-3 (AIO KRK-0306)
19. Development of a Predictive Score Using Amphiregulin (AREG), Epiregulin (EREG) and Egfr-Fish Expression Levels to Determine Treatment Efficacy in Mcrc Patients Receiving Cetuximab-Based Therapy. Analysis of the German AIO CRC-0104 Trial
20. Effective Management of Chemotherapy-Induced Anaemia in Clinical Practice using Darbepoetin Alfa: Final Data from the Correct II Study
21. The Charateristics of Palliative Care in a Rural European Region
22. Early Tumor Shrinkage (ETS) For the Prediction of Efficacy in Metastatic Colorectal Cancer (MCRC): Post-Hoc Analysis from an Irinotecan-Based Randomized First-Line Trial
23. LBA11 - Independent Radiological Evaluation of Objective Response, Early Tumor Shrinkage, and Depth of Response in Fire-3 (Aio Krk-0306) in the Final Ras Evaluable Population
24. 1530P - The Mobile Oncological Service for Out-Patients (Mod): Analysis of Cost Effectiveness and Quality of Life in the First Quarters of Action
25. 1346P - Network Kids: a Project for Children of Cancer Patients. Analyses of Impact on Quality of Life and Coping for Families Affected
26. 508PD - 2Nd-Line Therapies After 1St-Line Therapy with Folfiri in Combination with Cetuximab or Bevacizumab in Patients with Kras Wild-Type Metastatic Colorectal Cancer (Mcrc)-Analysis of the Aio Krk 0306 (Fire 3)- Trial
27. O-0030 - Independent Radiological Evaluation of Objective Response Early Tumor Shrinkage, and Depth of Response in FIRE-3 (AIO KRK-0306)
28. O-0018 - 2ND-Line Therapies After 1st-Line Therapy with Folfiri in Combination with Cetuximab or Bevacizumab in Patients with KRAS Wild-Type Metastatic Colorectal Cancer (MCRC)-Analysis of the AIO KRK 0306 (FIRE 3)- Trial
29. 1567P - Effective Management of Chemotherapy-Induced Anaemia in Clinical Practice using Darbepoetin Alfa: Final Data from the Correct II Study
30. 1435P - The Charateristics of Palliative Care in a Rural European Region
31. 599P - Early Tumor Shrinkage (ETS) For the Prediction of Efficacy in Metastatic Colorectal Cancer (MCRC): Post-Hoc Analysis from an Irinotecan-Based Randomized First-Line Trial
32. 526PD - Development of a Predictive Score Using Amphiregulin (AREG), Epiregulin (EREG) and Egfr-Fish Expression Levels to Determine Treatment Efficacy in Mcrc Patients Receiving Cetuximab-Based Therapy. Analysis of the German AIO CRC-0104 Trial
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.